Compare BDSX & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BDSX | TNYA |
|---|---|---|
| Founded | 2005 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precision Instruments | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 143.2M | 171.4M |
| IPO Year | 2020 | 2021 |
| Metric | BDSX | TNYA |
|---|---|---|
| Price | $14.59 | $0.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $32.50 | $5.33 |
| AVG Volume (30 Days) | 64.7K | ★ 4.7M |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.96 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $88,499,000.00 | N/A |
| Revenue This Year | $25.26 | N/A |
| Revenue Next Year | $19.15 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 24.08 | N/A |
| 52 Week Low | $0.26 | $0.43 |
| 52 Week High | $20.21 | $2.35 |
| Indicator | BDSX | TNYA |
|---|---|---|
| Relative Strength Index (RSI) | 55.64 | 47.82 |
| Support Level | $13.46 | $0.65 |
| Resistance Level | $16.38 | $0.82 |
| Average True Range (ATR) | 1.00 | 0.09 |
| MACD | 0.08 | -0.01 |
| Stochastic Oscillator | 42.83 | 9.22 |
Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.